ZIC2 and neoplasm: This alignment between experimental and bioinformatics data validates ZIC2 as a reliable biomarker for BC and suggests its involvement in tumor progression and lymphatic metastasis through modulation of the tumor microenvironment, particularly lymphangiogenesis.